Overview

Also Known As:IR^Lox

These IR^lox mutant mice have loxP sites flanking exon 4 of the targeted gene. When bred to Cre-recombinase expressing mice, offspring will have a deletion of exon 4 in the cre expressing tissue(s). These floxed mice may be useful in studying insulin receptor function in several different tissues (including pancreas, liver, and skeletal muscle), as well as diabetes and glucose regulation.

Donating Investigator

C. Ronald Kahn, Joslin Diabetes Center

Genetic overview

Genetic Background	Generation
	N11+N1F7 (2020-03-19 00:00:00)

Insr^tm1Khn

Allele Type	Gene Symbol	Gene Name
Targeted (Conditional ready (e.g. floxed), No functional change)	Insr	insulin receptor

View Genetics

Research Applications

Research Tools
Diabetes and Obesity Research

View All Research Applications

Base Price

Starting at:

$255.00 Domestic price for female 4-week

View Price List

Details

Detailed Description

Mice homozygous for this IR^lox allele are viable and fertile. These mutant mice have loxP sites flanking exon 4 of the targeted gene. When bred to Cre-recombinase expressing mice, offspring will have a deletion of exon 4 in the cre expressing tissue(s). These "floxed" mice may be useful in studying insulin receptor function in several different tissues (including pancreas, liver, and skeletal muscle), as well as diabetes and glucose regulation.

For example, when crossed to a strain expressing Cre recombinase in the central and peripheral nervous system (see Stock No. 003771), this mutant mouse strain may be useful in studies of glucose homeostasis.

When crossed to a strain expressing Cre recombinase in skeletal and cardiac muscle (see Stock No. 006475), this mutant mouse strain may be useful in studies of diabetes.

When crossed to a strain expressing Cre recombinase in the liver (see Stock No. 003574), this mutant mouse strain may be useful in studies of insulin resistance.

When crossed to a strain expressing Cre recombinase in pancreatic beta cells (see Stock No. 003573), this mutant mouse strain may be useful in studies of diabetes.

Development

A targeting vector was designed to insert a loxP-flanked neomycin cassette downstream of exon 4, as well as a single loxP site 80 bp downstream of exon 4 of the targeted gene. The construct was electroporated into the 129S4/SvJae-derived J1 embryonic stem (ES) cells. ES cell were transiently transfected with a Cre-recombinase plasmid to delete the selection cassette, leaving single loxP sites upstream and downstream of exon 4. Correctly targeted ES cells were injected into C57BL/6J blastocysts, which were injected into pseudopregnant CD-1 foster females. The resulting mutant mice (IR^lox) were backcrossed to C57BL/6J inbred mice. At some point, mice were bred to Mck-Cre transgenic mice (FVB genetic background, see Stock No. 006405). The double mutants were backcrossed for 10 generations to C57BL/6 mice and then selected for the IR^lox (and against the transgene) prior to arrival at The Jackson Laboratory.

A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, all 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating. These data suggest the mice sent to The Jackson Laboratory Repository were on a C57BL/6N genetic background.

Control Suggestions

Approximate Controls

Additional Information

Considerations for Choosing Controls

Selected References

Bruning JC; Michael MD; Winnay JN; Hayashi T; Horsch D; Accili D; Goodyear LJ; Kahn CR. 1998. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2(5):559-69PubMed: 9844629 MGI: J:51266

View All References

Genetics

Insr^tm1Khn

Allele Symbol: Insr^tm1Khn

Allele Name	targeted mutation 1, Ronald Kahn
Allele Type	Targeted (Conditional ready (e.g. floxed), No functional change)
Allele Synonym(s)	Insr^flox; IR(lox); IR^flox; IR^Lox; IRlox
Gene Symbol and Name	Insr, insulin receptor
Gene Synonym(s)
Strain of Origin	129S4/SvJae
Chromosome	8
General Note	In conjunction with Tg(Mycha-cre)1Abel, this allele is knocked out specifically in cardiac muscle. The resulting mice are referred to as "Cardiac-specific insulin receptor knockout mice" or CIRKO. In conjunction with Tg(Ckmm-cre)5Khn, this allele is disrupted specifically in skeletal muscle. The resulting mice are referred to as "Muscle-specific insulin receptor knockout mice" or MIRKO.
Molecular Note	Exon 4 was left flanked by single loxP sites after a downstream floxed neo cassette was removed via in vitro cre mediated recombination. Deletion of the resultant floxed fragment will result in a frameshift mutation that introduces a stop codon. Translation, if it were to occur, would putatively produce a truncated peptide consisting of 308 amino terminal residues and lacking the high affinity binding site, transmembrane domain, and kinase domain.
Mutations Made By	C. Ronald Kahn, Joslin Diabetes Center

Disease/Phenotype

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Research Tools
- Diabetes and Obesity Research
  - loxP
- Cre-lox System
  - loxP-flanked Sequences
Diabetes and Obesity Research
- Insulin Receptors and Growth Factors

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
involves: 129S4/SvJae * C57BL/6 * DBA/2

endocrine/exocrine gland phenotype

increased pancreatic beta cell mass
- at 2 weeks beta cell mass is increased 2-fold and at 6 weeks 4-fold compared to in wild-type mice due to increased mitosis of beta cells
- at 10 to 12 months of age, mice exhibit a 27-fold increase in beta cell mass due to an 8-fold increase in proliferating beta cells with a slight increase in apoptosis

homeostasis/metabolism phenotype

insulin resistance

increased circulating insulin level

impaired glucose tolerance

hyperglycemia
- while mice display normoglycemia during the first 3 weeks of life, at 4 weeks mice develop hypoglycemia that lasts until week 6

decreased circulating glucose level
- at 10 to 12 months of age

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * DBA/2

endocrine/exocrine gland phenotype

decreased pancreatic beta cell mass
- mice exhibit decreased beta cell mass when fed a normal or high fat diet

decreased insulin secretion

homeostasis/metabolism phenotype

impaired glucose tolerance
- mice exhibit impaired glucose tolerance on a normal diet and severe intolerance when fed a high fat diet
- Normal - however, mice are not insulin resistant

hyperglycemia
- mice exhibit an increase in serum glucose level on a regular diet and a severe increase when fed a high fat diet

decreased insulin secretion

mortality/aging

premature death
- some mice die due to severe hyperglycemia

increased sensitivity to induced morbidity/mortality
- when fed a high fat diet, 30% of mice die by 16 weeks

Genotype: Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * DBA/2

behavior/neurological phenotype

polydipsia
- during terminal stages

mammalian phenotype

digestive/alimentary phenotype
- Normal - unlike mice null for Insr in beta cells mice, islet cell mass is not increased despite similar levels of elevated insulin levels

mortality/aging

premature death
- 82% of mice die by 6 weeks of age with some mice surviving a few weeks longer

renal/urinary system phenotype

polyuria
- during terminal stages

endocrine/exocrine gland phenotype

decreased insulin secretion

growth/size/body region phenotype

decreased body weight
- mice develop severe diabetes and loss 30% of their body weight in terminal stages

homeostasis/metabolism phenotype

insulin resistance

increased circulating insulin level

impaired glucose tolerance

hyperglycemia
- mice exhibit high fasting glucose serum levels
- mice develop hypoglycemia at 2 weeks of age that rapidly worsens by 6 weeks of age

decreased insulin secretion

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * C57BL/6 * FVB

mammalian phenotype

homeostasis/metabolism phenotype
- Normal - mice exhibit normal glucose homeostasis

growth/size/body region phenotype
- Normal - mice exhibit normal growth rates

cardiovascular system phenotype
- Normal - heart function and morphology is normal

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Nes-cre)1Kln/0
involves: 129S4/SvJae * C57BL/6 * SJL

homeostasis/metabolism phenotype

abnormal glucose homeostasis
- insulin-induced suppression of hepatic glucose productionas assessed with a euglycemic hyperinsulinemic clamp is attenuated

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Nes-cre)1Kln/0
involves: 129S4/SvJae * C57BL/6J * SJL

endocrine/exocrine gland phenotype

Leydig cell hypoplasia

impaired ovarian folliculogenesis
- reduced number of antral follicles

decreased corpora lutea number

abnormal seminiferous tubule morphology
- normal seminal vesicles, prostate, and epididymis
- 20% of seminiferous tubules lacked a lumen and had few maturing spermatogonia

growth/size/body region phenotype

increased body weight
- on a high-fat diet, male mice exhibit a 10% weight increase at 14 weeks of age and females exhibit a 20% increase over controls
- males do not exhibit weight differences on a standard chow diet, but females exhibit a 10-15% increase over controls

adipose tissue phenotype

increased white adipose tissue amount
- in males, a 1.5-fold increase in adipose tissue is seen
- in females, a two-fold increase in perigonadal adipose tissue is seen

homeostasis/metabolism phenotype

insulin resistance
- females exhibit blunted response when injected with insulin and males performed similarly to controls

increased circulating triglyceride level
- both males and females exhibit a 30% increase in circulating triglycerides

increased circulating leptin level
- normal cholesterol concentrations
- 2.5 fold increased in females
- 1.5 fold increased in males

increased circulating insulin level
- normal glucose tolerance
- at 4-6 months of age, mice exhibit a 1.5 fold increase in circulating insulin levels and females exhibit a 2 fold increase

decreased circulating luteinizing hormone level
- normal pituitary morphology and LH content; treatment with lupron indicated that LH is expressed, but not secreted from the pituitary in mutant mice
- 20% of seminiferous tubules lacked a lumen and had few maturing spermatogonia

mammalian phenotype

nervous system phenotype
- Normal - brain weights and general brain histology appeared similar to controls

reproductive system phenotype

reduced male fertility

oligozoospermia
- 30% reduced in epididymal sperm content

Leydig cell hypoplasia

impaired ovarian folliculogenesis
- reduced number of antral follicles

decreased corpora lutea number

abnormal spermatogenesis
- impaired

abnormal seminiferous tubule morphology
- normal seminal vesicles, prostate, and epididymis
- 20% of seminiferous tubules lacked a lumen and had few maturing spermatogonia

behavior/neurological phenotype

polyphagia
- males did not exhibit any differences in food intake when compared to controls
- females exhibit a 20% increase in food intake per gram of body weight

cellular phenotype

oligozoospermia
- 30% reduced in epididymal sperm content

Genotype: Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
involves: 129S4/SvJae * C57BL/6J * DBA/2 * FVB

cellular phenotype

increased mitochondria size
- at 6 months, mutant hepatocytes exhibit giant mitochondria

homeostasis/metabolism phenotype

insulin resistance
- at 2 months, random-fed male mutants are severely resistant to the blood glucose-lowering effects of exogenously administered insulin

increased insulin secretion
- at 6 months, female mutants show a have 5- to 6-fold increase in pancreatic insulin content measured in acid-ethanol extracts

increased circulating insulin level
- at 2 months, male mutants exhibit an extreme increase in serum insulin levels (20-fold in fed state; 7-fold in fasted state)

increased circulating aspartate transaminase level
- in contrast, no significant changes in levels of lactate dehydrogenase or alanine aminotransferase are observed
- at 6 months, mutant mice show a 2.6-fold increase in aspartate aminotransferase levels, suggesting hepatocellular damage

increased circulating alkaline phosphatase level
- at 6 months, mutant mice show a 50% increase in alkaline phosphatase levels, suggesting biliary tract dysfunction

increased bile salt level
- mutant gallbladders show a notable increase in bile volume

impaired glucose tolerance
- surprisingly, glucose intolerance is no longer apparent at 6 months
- at 2 months, fasted male mutants display pronounced glucose intolerance

hyperglycemia
- unexpectedly, as mutant mice age, the elevated fasting blood glucose levels progressively decline; by 6 months of age, mutants exhibit fasting hypoglycemia rather than hyperglycemia
- at 2 months, male mutants exhibit significantly elevated blood glucose in the fed state, despite a 20-fold increase in insulin levels relative to control mice; in contrast, glucagon levels remain unaffected
- at 2 months, male mutants also display a mild hyperglycemia in the fasted state, despite a 7-fold increase in serum insulin levels

decreased circulating triglyceride level
- at 2 months, male mutants show a 40-50% reduction in the levels of serum triglycerides

decreased circulating free fatty acid level
- at 2 months, male mutants show a 40-50% reduction in the levels of serum free fatty acids

abnormal lipid homeostasis

abnormal insulin clearance
- in addition to increased insulin secretion, 11-week-old male mutants show a 75% reduction in the C-peptide:insulin ratio, indicating decreased insulin clearance

abnormal glucose homeostasis
- at 2 months, male mutants fail to suppress hepatic glucose output in response to insulin administration, despite intact insulin signaling in adipose tissue and nearly normal insulin signaling in muscle

abnormal circulating serum albumin level
- at 6 months, mutant mice display a 50% reduction in serum albumin levels

liver/biliary system phenotype

small liver
- at 2 months, mutant livers are 40% smaller than those of age- and gender-matched controls; liver size decreases significantly with increasing age

enlarged gallbladder
- at 6- to 12-months of age, mutant gall bladders appear enlarged

abnormal liver physiology
- the mutant liver appears to be chronically geared toward glucose production; early insulin signaling events, such as IRS-1 and IRS-2 phosphorylation, are lost
- insulin resistance in liver results in elevated expression of PEPCK, the rate-limiting enzyme for gluconeogenesis, and reduced expression of glucokinase and liver pyruvate kinase, two enzymes critical for glucose utilization

abnormal liver morphology
- by 12 months, the normal lobular structure is disrupted; hyperplastic nodules consist of highly vacuolated cells that compress the adjacent normal tissue, in the absence of fibrosis
- at 6- to 12-months of age, mutant livers display multiple hyperplastic pale nodules scattered throughout all lobes
- at 2 months, mutant livers appear a little darker in color, with areas of focal dysplasia and reduced glycogen storage in the parenchyma; no steatosis is observed

abnormal hepatocyte morphology
- at 6 months, mutant hepatocytes exhibit a moderate increase in lipid accumulation; only a few electron-dense glycogen granules are observed

endocrine/exocrine gland phenotype

pancreatic islet hyperplasia
- at 6 months, mutant mice show an adaptive islet hyperplastic response to insulin resistance

increased pancreatic beta cell mass
- at 6 months, mutant mice show a ~4-fold increase in pancreatic beta cell mass, as a compensatory response to insulin resistance
- at 6 months, increased pancreatic insulin content is associated with a 6-fold increase in pancreatic beta cell mass

increased insulin secretion
- at 6 months, female mutants show a have 5- to 6-fold increase in pancreatic insulin content measured in acid-ethanol extracts

enlarged gallbladder
- at 6- to 12-months of age, mutant gall bladders appear enlarged

growth/size/body region phenotype

postnatal growth retardation
- this moderate growth deficit appears to result from defects in the growth hormone-IGF axis (unpublished data)
- newborn mutant mice appear normal, nurse successfully, and survive well upon weaning but display a mild growth deficit postweaning

enlarged gallbladder
- at 6- to 12-months of age, mutant gall bladders appear enlarged

Genotype: Insr^tm1Khn/Insr^tm1Dac Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * C57BL/6J * FVB

homeostasis/metabolism phenotype

increased circulating insulin level

hyperglycemia
- in the fed state, incomplete penetrance

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * C57BL/6J * FVB

adipose tissue phenotype

abnormal fat pad morphology
- larger than normal fat depots in fat pads, including the perianal, subcutaneous and perigonadal fat pads

homeostasis/metabolism phenotype

increased triglyceride level
- greater than70% elevated, observed from ages 4 to 11 months

increased fatty acid level
- 20% elevation in serum free fatty acids (FFAs)

mammalian phenotype

homeostasis/metabolism phenotype
- Normal - normoglycemia, up to 11 months of age
- Normal - normal serum cholesterol levels
- Normal - normal glucose tolerance
- Normal - normal concentrations of serum insulin

References

Bruning JC; Michael MD; Winnay JN; Hayashi T; Horsch D; Accili D; Goodyear LJ; Kahn CR. 1998. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2(5):559-69PubMed: 9844629 MGI: J:51266

Additional References

Mezza T; Shirakawa J; Martinez R; Hu J; Giaccari A; Kulkarni RN. 2016. Nuclear Export of FoxO1 Is Associated with ERK Signaling in beta-Cells Lacking Insulin Receptors. J Biol Chem 291(41):21485-21495PubMed: 27535223 MGI: J:237303
Tarchick MJ; Cutler AH; Trobenter TD; Kozlowski MR; Makowski ER; Holoman N; Shao J; Shen B; Anand-Apte B; Samuels IS. 2019. Endogenous insulin signaling in the RPE contributes to the maintenance of rod photoreceptor function in diabetes. Exp Eye Res 180:63-74PubMed: 30543793 MGI: J:281341

Additional - Insr^tm1Khn related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Standard PCR:Insr Alternate1
- Standard PCR:Generic Neo
- Probe:Generic Neo
- Genotyping resources and troubleshooting
Dietary Information
- LabDiet® 5K52 formulation (6% fat)
Breeding Considerations

When maintaining a live colony, homozygous mice are bred.
- Additional Breeding and Husbandry Support
Mating System
- Homozygote x Homozygote
Citation
When using the IR^Lox mouse strain in a publication, please cite the originating article(s) and include JAX stock #006955 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX10 (Standard)

Pricing & Availability

Available

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service/Product	Description	Price
	Heterozygous for Insr<tm1Khn>

Related Products and Services

Frozen Mouse Embryo	B6.129S4(FVB)-Insr<tm1Khn>/J	$2595.00
Frozen Mouse Embryo	B6.129S4(FVB)-Insr<tm1Khn>/J	$2595.00
Frozen Mouse Embryo	B6.129S4(FVB)-Insr<tm1Khn>/J	$3373.50
Frozen Mouse Embryo	B6.129S4(FVB)-Insr<tm1Khn>/J	$3373.50

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.

Terms Of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As:IRLox

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Control Suggestions

Approximate Controls

Additional Information

Selected References

Insrtm1Khn

Allele Symbol: Insrtm1Khn

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Insrtm1Khn/Insrtm1Khn Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+involves: 129S4/SvJae * C57BL/6 * DBA/2

endocrine/exocrine gland phenotype

homeostasis/metabolism phenotype

Genotype: Insrtm1Khn/Insrtm1Khn Tg(Ins2-cre)25Mgn/0involves: 129S4/SvJae * C57BL/6 * DBA/2

endocrine/exocrine gland phenotype

homeostasis/metabolism phenotype

mortality/aging

Genotype: Insrtm1Khn/Insrtm1Khn Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ Tg(Ins2-cre)25Mgn/0involves: 129S4/SvJae * C57BL/6 * DBA/2

behavior/neurological phenotype

mammalian phenotype

mortality/aging

renal/urinary system phenotype

endocrine/exocrine gland phenotype

growth/size/body region phenotype

homeostasis/metabolism phenotype

Genotype: Insrtm1Khn/Insrtm1Khn Tg(Ckmm-cre)5Khn/0involves: 129S4/SvJae * C57BL/6 * FVB

mammalian phenotype

Genotype: Insrtm1Khn/Insrtm1Khn Tg(Nes-cre)1Kln/0involves: 129S4/SvJae * C57BL/6 * SJL

homeostasis/metabolism phenotype

Genotype: Insrtm1Khn/Insrtm1Khn Tg(Nes-cre)1Kln/0involves: 129S4/SvJae * C57BL/6J * SJL

endocrine/exocrine gland phenotype

growth/size/body region phenotype

adipose tissue phenotype

homeostasis/metabolism phenotype

mammalian phenotype

reproductive system phenotype

behavior/neurological phenotype

cellular phenotype

Genotype: Insrtm1Khn/Insrtm1Khn Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+involves: 129S4/SvJae * C57BL/6J * DBA/2 * FVB

cellular phenotype

homeostasis/metabolism phenotype

liver/biliary system phenotype

endocrine/exocrine gland phenotype

growth/size/body region phenotype

Genotype: Insrtm1Khn/Insrtm1Dac Tg(Ckmm-cre)5Khn/0involves: 129S4/SvJae * C57BL/6J * FVB

homeostasis/metabolism phenotype

Genotype: Insrtm1Khn/Insrtm1Khn Tg(Ckmm-cre)5Khn/0involves: 129S4/SvJae * C57BL/6J * FVB

adipose tissue phenotype

homeostasis/metabolism phenotype

mammalian phenotype

References

Additional References

Additional - Insrtm1Khn related

Genotyping Protocols

Dietary Information

Breeding Considerations

Mating System

Citation

Animal Health Reports

Live Mouse

Cryorecovery - Pricing

Related Products and Services

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms Of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Also Known As:IR^Lox

Insr^tm1Khn

Allele Symbol: Insr^tm1Khn

Genotype: Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
involves: 129S4/SvJae * C57BL/6 * DBA/2

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * DBA/2

Genotype: Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * DBA/2

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * C57BL/6 * FVB

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Nes-cre)1Kln/0
involves: 129S4/SvJae * C57BL/6 * SJL

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Nes-cre)1Kln/0
involves: 129S4/SvJae * C57BL/6J * SJL

Genotype: Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
involves: 129S4/SvJae * C57BL/6J * DBA/2 * FVB

Genotype: Insr^tm1Khn/Insr^tm1Dac Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * C57BL/6J * FVB

Genotype: Insr^tm1Khn/Insr^tm1Khn Tg(Ckmm-cre)5Khn/0
involves: 129S4/SvJae * C57BL/6J * FVB

Additional - Insr^tm1Khn related